{"product_id":"avanos-bcg-matrix","title":"Avanos Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuick snapshot: the Avanos BCG Matrix shows which product lines are fueling growth, which are steady cash cows, and which could be costing you momentum — or deserve a rethink. This preview scratches the surface; buy the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word report plus an Excel summary. Get clarity fast and start reallocating capital where it actually moves the needle—purchase now for instant access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑opioid RF pain therapy platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos’s cooled radiofrequency pain therapy sits in a fast‑growing non‑opioid niche with strong clinician pull, leading procedures across many IDNs and ASC pain programs but still requiring aggressive education and placement support.\u003c\/p\u003e\n\u003cp\u003eKeeping share as the category expands can turn this engine into a long‑run cash generator; strategy focuses on investing in training, KOL engagement, and site‑of‑service expansion to capture durable adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional anesthesia \u0026amp; nerve block portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2024 ERAS protocols and growth in outpatient surgery are driving rising adoption of nerve block catheters and accessories, with utilization climbing where Avanos holds contracts. Share remains solid in contracted accounts and shows leader‑like behavior in this expanding segment, though it still requires promotional spend, in‑service time, and clinical support. Continue investing in training, sampling, and clinical outcomes data to feed the flywheel and lock in preference and scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnteral access navigation system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe guided placement platform for feeding tubes reduces placement complications and speeds time to nutrition, matching hospital priorities for safety and throughput. Adoption curves are steep where clinical champions exist and the disposable pull-through consumable drives recurring revenue opportunities. Requires installs, training and field service so near-term cash in ≈ cash out; invest to densify the installed base and convert competitors. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClosed suction systems for ventilated patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClosed suction systems for ventilated patients are a Stars category: infection-prevention and ICU-efficiency drivers keep demand rising, with Avanos frequently specified; the global closed-suction market was about $550M in 2024 with ~6% CAGR, supporting high utilization. Strong clinical evidence and workflow fit sustain use while expansion into step-down and ward settings adds runway, though sales still require clinical outcomes selling and placement work.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInfection reduction: validated VAE\/ventilator-associated pneumonia reductions\u003c\/li\u003e\n\u003cli\u003eMarket: ~$550M (2024), ~6% CAGR\u003c\/li\u003e\n\u003cli\u003eSales: clinical outcomes + placement efforts needed\u003c\/li\u003e\n\u003cli\u003eGrowth: expansion into new care settings and indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost‑op pain pumps used in ambulatory settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-op pain pumps in ambulatory joints and soft-tissue cases benefit from the outpatient shift, driving demand for non-opioid analgesia; high awareness, protocolized use, and predictable reorders position Avanos as a leader, though uptake depends on provider education, anesthesia-surgeon alignment, and reliable supply chains. Invest to harden standard-of-care status across key procedures.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket fit: outpatient shift supports non-opioid solutions\u003c\/li\u003e\n\u003cli\u003eOperational strengths: protocolization and repeat reorders\u003c\/li\u003e\n\u003cli\u003eGaps: education, clinical alignment, supply reliability\u003c\/li\u003e\n\u003cli\u003eRecommendation: invest to cement SOC across target procedures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinician-led device niches with recurring consumables, invest in installs, training, outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos Stars (cooled RFA, nerve‑block catheters, guided feeding platforms, closed‑suction, postop pumps) occupy fast‑growing, clinician‑led niches with recurring consumables and strong protocol tailwinds.\u003c\/p\u003e\n\u003cp\u003eClosed‑suction global market ≈ $550M (2024), ~6% CAGR; other segments show double‑digit adoption in ASC\/ERAS pockets.\u003c\/p\u003e\n\u003cp\u003ePriority: invest in installs, training, KOLs, outcomes data to convert use into durable cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Market\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eKey actions\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClosed suction\u003c\/td\u003e\n\u003ctd\u003e$550M\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003ctd\u003eClinical outcomes, expand to wards\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain\/nerve catheters \u0026amp; pumps\u003c\/td\u003e\n\u003ctd\u003eHigh-growth (double-digit pockets)\u003c\/td\u003e\n\u003ctd\u003eGD\u003c\/td\u003e\n\u003ctd\u003eTraining, sampling, SOC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG Matrix review of Avanos products: Stars, Cash Cows, Question Marks, Dogs with action recommendations and market context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Avanos BCG Matrix pinpoints winners and laggards for fast, C-level clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard enteral feeding tubes \u0026amp; sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard enteral feeding tubes and sets are a mature, contracted cash cow for Avanos—hospital reorder rates exceed 90% and the global enteral feeding market was ~$2.2B in 2024, so muscle‑memory purchasing sustains volume. Tight manufacturing and simple service sustain healthy gross margins (~35–40%), while segment growth is modest (~2–4% annually), so promotion remains light. Milk efficiency, protect price, and redeploy cash to higher‑growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTracheostomy care and suction consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge installed base—about 100,000 tracheostomy patients\/year in the US—plus routine use and stable care protocols keep volumes steady for Avanos’ tracheostomy care and suction consumables. Differentiation is modest but reliable, with low market growth (~2–3% CAGR in 2024) meaning low spend to maintain share. Optimize supply chain and lean into GPO renewals to preserve cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOR and ICU procedure kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOR and ICU procedure kits are sticky: packaged convenience and entrenched workflows drive high retention, with Avanos reporting FY2024 revenue of $1.16B and procedure consumables as a stable recurring base. Switching costs are operational rather than clinical, favoring incumbents and preserving share. Margins scale from standardization and volume; maintain contracts, trim SKU complexity, and bank the contribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy pain disposables with steady reorder\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eLegacy pain disposables with steady reorder\u003c\/h3\u003eThese dependable lines rarely headline but drive recurring purchase orders; market growth is flat in 2024 while share remains durable in long‑standing accounts. Minimal detailing beyond service and pricing discipline keeps cost-to-serve low; strategy is to harvest cash and defend the base.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDependable recurring orders\u003c\/li\u003e\n\u003cli\u003eFlat market growth 2024\u003c\/li\u003e\n\u003cli\u003eDurable account share\u003c\/li\u003e\n\u003cli\u003eLow sales intensity, pricing focus\u003c\/li\u003e\n\u003cli\u003eHarvest cash, defend base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eService contracts on installed enteral systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eService contracts on installed enteral systems deliver predictable, high-margin annuity cash flows that fund R\u0026amp;D and ops; Avanos reported approximately $1.43 billion in revenue in fiscal 2024, with installed-base services underpinning recurring income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePredictable revenue: steady renewals\u003c\/li\u003e\n\u003cli\u003eLow variable cost: high margin contribution\u003c\/li\u003e\n\u003cli\u003eRenewal cycles: well understood, low drama\u003c\/li\u003e\n\u003cli\u003eGrowth limit: footprint-constrained\u003c\/li\u003e\n\u003cli\u003eActions: maximize uptime, automate renewals, allocate cash to innovation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash cows: \u003cstrong\u003e$1.43B\u003c\/strong\u003e, enteral $2.2B, \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e reorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStandard enteral feeding, tracheostomy consumables, OR\/ICU kits and legacy pain disposables form Avanos cash cows: FY2024 revenue ~1.43B with enteral market ~$2.2B (2024). High reorder (\u0026gt;90%), low growth (2–4% CAGR), margins ~35–40% sustain free cash for R\u0026amp;D and M\u0026amp;A.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eFY24 rev\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnteral\u003c\/td\u003e\n\u003ctd\u003e~$?B\u003c\/td\u003e\n\u003ctd\u003e2–4%\u003c\/td\u003e\n\u003ctd\u003e35–40%\u003c\/td\u003e\n\u003ctd\u003eProtect price\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTracheostomy\u003c\/td\u003e\n\u003ctd\u003epart of base\u003c\/td\u003e\n\u003ctd\u003e2–3%\u003c\/td\u003e\n\u003ctd\u003e30–35%\u003c\/td\u003e\n\u003ctd\u003eGPO renewals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAvanos BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing here is the exact Avanos BCG Matrix report you'll receive after purchase. No watermarks, no demo text—just a fully formatted, analysis-ready document designed by strategy experts. Once you buy, the same file is immediately downloadable and editable for presentations, planning, or investor pitches. No surprises, no extra edits needed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163506028921,"sku":"avanos-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/avanos-bcg-matrix.png?v=1762721442","url":"https:\/\/portersfiveforce.com\/products\/avanos-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}